RxDoctor Payments Data

Kristen Leany, APRN

Family · Saint George, UTNPI 1396238630

Payments from drug & device makers

$3,163in general payments, 2019–2025

Across 117 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$509
  • Amgen$355
  • Novo Nordisk$281
  • Johnson & Johnson$273
  • Boston Scientific$267
  • Actelion Pharmaceuticals US, Inc.$251
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,163 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$147,572
Medicare patients
692
Services billed
2,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$261,532
XareltoRivaroxaban153$200,410
EntrestoSacubitril/Valsartan34$57,139
Repatha SureclickEvolocumab28$24,937
MounjaroTirzepatide12$12,074
Metoprolol Succinate350$4,781
Amiodarone Hcl90$2,933
Rosuvastatin Calcium185$2,899
Atorvastatin Calcium261$2,294
Dabigatran EtexilateDabigatran Etexilate Mesylate13$1,852
Losartan Potassium211$1,794
Potassium Chloride114$1,671
ClopidogrelClopidogrel Bisulfate111$1,440
Amlodipine Besylate206$1,430
Prasugrel Hcl20$1,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$176$261,532211 claims
Johnson & JohnsonXarelto$273$200,410153 claims
NovartisEntresto$190$57,13934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.

Other family in Saint George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →